SCHEMBL2020383

SCHEMBL2020383

O=[C][C@H]1O[C@@H]1[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL851929 1.00
SCHEMBL570096 0.55
SCHEMBL9580055 0.53
SCHEMBL3613017 0.49
SCHEMBL76224 0.49
SCHEMBL11320944 0.46
SCHEMBL3480866 0.46
SCHEMBL3181343 0.46
Barium SCHEMBL31634889 0.46
SCHEMBL30688973 0.46

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150106974-A1 PLANTS HAVING ENHANCED YIELD-RELATED TRAITS AND A METHOD FOR MAKING THE SAME BASF PLANT SCIENCE COMPANY GMBH (DE) 2015-04-16 US disclosed
US-20110162110-A1 THE AN3 Protein Complex and its Use for Plant Growth Promotion BASF PLANT SCIENCE COMPANY GMBH (DE) 2011-06-30 US disclosed
US-20070160531-A1 Targeting endothelium for tissue-specific delivery of agents SCHNITZER JAN E 2007-07-12 US disclosed
WO-1997034629-A1 IMMUNOGENIC COMPOSITIONS COMPRISING PORPHYROMONAS GINGIVALIS PEPTIDES AND METHODS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1997-09-25 WO disclosed
WO-1993000926-A1 TREATMENT OF PERIODONTAL DISEASE WITH PROTEASE INHIBITORS CHILDREN'S MEDICAL CENTER CORPORATION (US) 1993-01-21 WO disclosed
US-4927965-A ENDOTHELIAL WOUND HEALING; TREATMENT OF MALIGNANT HYPERCALCEMIA MERCK & CO., INC. (US) 1990-05-22 US disclosed
EP-0367601-A1 N-(N-succinyl-l-leucyl) agmatine, related compounds and use in pharmacology MERCK & CO. INC. (US) 1990-05-09 EP disclosed
EP-0269311-A2 Methods of treating bone diseases by administration of a cysteine proteinase inhibitor MERCK & CO. INC. (US) 1988-06-01 EP disclosed